Pfizer-BioNTech, Moderna, et Janssen de Johnson & Johnson sont les trois vaccins COVID-19 autorisés pour une utilisation d’urgence aux Etats-Unis. Cette étude a pour but d’analyser et de comparer les effets indésirables suivant l’immunisation (AEFI) associés à ces vaccins COVID-19 sur la base des données du Vaccine Adverse Effect Reporting System (VAERS).
Background/Aim Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen are the three COVID-19 vaccines authorized for emergency use in the United States. This study aims to analyze and compare adverse events following immunization (AEFIs) associated with these COVID-19 vaccines based on Vaccine Adverse Effect Reporting System (VAERS) data. Methods We utilized VAERS data from 1st Jan 2021 to 30th April 2021 to analyze and characterize adverse effects post-vaccination with these authorized COVID-19 vaccines in the US population. Results A total of 141208 individuals suffered at least one AEFI following 239.97 million doses of COVID-19 vaccination. The frequency of side effects was 0.04%, 0.06%, and 0.35% following administration of Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen vaccines, respectively. Most of the patients had mild systemic side effects, the most common being headache (0.01%) and fever (0.01%). The frequency of serious side effects including anaphylaxis (0.0003%) and death (0.002%) was extremely low. Conclusion The three COVID 19 vaccines have a wide safety profile with only minor and self-limiting adverse effects. However, continued monitoring ad surveillance is required to review any unexpected serious adverse effects.